Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An ACromegaly, Open-label, Multi-CEnter, Safety Monitoring Program for Treating Patients With SOM230 (Pasireotide) LAR Who Have Need to Receive Medical Therapy

Trial Profile

An ACromegaly, Open-label, Multi-CEnter, Safety Monitoring Program for Treating Patients With SOM230 (Pasireotide) LAR Who Have Need to Receive Medical Therapy

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Jan 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Acromegaly
  • Focus Adverse reactions; Expanded access
  • Acronyms ACCESS
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Apr 2016 Results presented at The 98th Annual Meeting of the Endocrine Society.
    • 05 Nov 2015 Status changed from completed to recruiting, as reported by ClinicalTrials.gov record
    • 05 Jun 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top